Utfordringer med svarte leirskifere; mellomlagring og naturlige blandmasser

Det er planlagt flere store byggeprosjekt i Oslo-regionen de neste årene. Dette vil resultere i utgraving av potensielt syredannende svart leirskifer i volumer som er større enn kapasiteten til godkjente deponier. NGI har et internt forskningsprosjekt «Under Oslo» som fokuserer på innovasjon, bærekraft og økonomi knyttet til underjordiske byggearbeider. Delprosjekt 1 omhandler svarte leirskifere. Svarte leirskifre er sedimentære bergarter med høyt innhold av sulfider, organisk materiale, tungmetaller og naturlig forekommende radionuklider. Riktig håndtering under prosjektgjennomføring og korrekt varig lagring av utgravde masser er avgjørende for å unngå forvitring og sur avrenning, som kan føre til skader på konstruksjoner og miljø. Mellomlagring kan være nødvendig for logistiske formål og for å gi mulighet for forsvarlig karakterisering av utgravde masser, mens langvarig midlertidig lagring kan gi negative effekter på miljøet. For å få bedre forståelse av tidsforløpet i forvitring og syredanning, er det samlet inn historiske data og startet opp utlekkingseksperimenter i konteinere. Tilgjengelige data fra storskala forsøk så langt indikerer at det går mer enn ett år før forvitring av frisk (uforvitret) skifer gir sur utlekking. Basert på disse dataene anbefales maksimum 6 måneder mellomlagring av uforvitret skifer – fordelt på byggeplass og deponi. Ved sprengning og utgraving kan det å skille svartskifer fra omkringliggende steinmasser være vanskelig, noe som resulterer i store mengder masser med en mindre andel svartskifer. De syredannende egenskapene til slike blandede masser er vanskelig å fastslå, og som følge av dette havner store mengder potensielt trygge masser på deponi. Konteiner- og kolonneforsøk med opptil 20 % innhold av alunskifer har etter 2 år ingen pH senkning, men det kan ikke utelukkes at dette vil komme på et senere tidspunkt. Ledningsevne og metallinnhold i avrenningen øker med økende skiferinnhold og tyder på høyere reaktivitet. Den aller beste håndteringen av svartskifer er å la den ligge uforstyrret i bakken. Kan man planlegge prosjekter slik at man tar ut minst mulig potensielt syredannende berg

The Triarchic Psychopathy Measure (TriPM): alternative to the PCL-R?

Psychopathic personality disorder is the subject of many research papers and in particular in the context of forensic settings, where its link to risk of future violence has been established. This topic is well examined but there is still considerable debate about the nature of the construct and how psychopathy is measured. Contemporary models such as the triarchic theory (Patrick, Fowles & Krueger, 2009) have been put forward yet the research into psychopathy tends to rely on one assessment tool, the Psychopathy Checklist-Revised (PCL-R; Hare, 2003) that is argued not to capture elements of psychopathy such as boldness. The Triarchic Psychopathy Measure (TriPM; Patrick, 2010) is a measure that is based on the triarchic theory, and it places an equal focus on boldness when measuring psychopathy. It is however a self-report instrument, and this approach has many limitations. This paper aims to review the scientific support for the TriPM and to discuss its potential application to clinical practice. It concludes that the TriPM may not yet be a contender for the PCL-R throne as the sole tool of choice for psychopathy measurement, but the research into the application of the TriPM is expanding our understanding of psychopathy as a construct

Healthy living on a healthy planet - Summary

Unsere Lebensweise macht krank und zerstört die natürlichen Lebensgrundlagen. In der Vision „Gesund leben auf einer gesunden Erde“ werden menschliche Lebensbereiche – Ernähren, Bewegen, Wohnen – gesund und umweltverträglich gestaltet sowie planetare Risiken – Klimawandel, Biodiversitätsverlust, Verschmutzung – bewältigt. Gesundheitssysteme nutzen ihre transformativen Potenziale, Bildung und Wissenschaft befördern gesellschaftliche Veränderungen. Die Vision ist nur mit internationaler Kooperation realisierbar und erfordert eine globale Dringlichkeitsgovernance.Our lifestyle is making us ill and is destroying the natural life-support systems. In the vision of ‘healthy living on a healthy planet’, human spheres of life – what we eat, how we move, where we live – are designed to be both healthy and environmentally compatible, and planetary risks – climate change, biodiversity loss, pollution – have been overcome. Health systems harness their transformative potential; education and science promote societal change. The vision can only be realized with international cooperation and requires what the WBGU terms global urgency governance

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators. Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm). Conclusions: Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies

Multi-messenger observations of a binary neutron star merger

On 2017 August 17 a binary neutron star coalescence candidate (later designated GW170817) with merger time 12:41:04 UTC was observed through gravitational waves by the Advanced LIGO and Advanced Virgo detectors. The Fermi Gamma-ray Burst Monitor independently detected a gamma-ray burst (GRB 170817A) with a time delay of ~1.7 s with respect to the merger time. From the gravitational-wave signal, the source was initially localized to a sky region of 31 deg2 at a luminosity distance of 40+8-8 Mpc and with component masses consistent with neutron stars. The component masses were later measured to be in the range 0.86 to 2.26 Mo. An extensive observing campaign was launched across the electromagnetic spectrum leading to the discovery of a bright optical transient (SSS17a, now with the IAU identification of AT 2017gfo) in NGC 4993 (at ~40 Mpc) less than 11 hours after the merger by the One- Meter, Two Hemisphere (1M2H) team using the 1 m Swope Telescope. The optical transient was independently detected by multiple teams within an hour. Subsequent observations targeted the object and its environment. Early ultraviolet observations revealed a blue transient that faded within 48 hours. Optical and infrared observations showed a redward evolution over ~10 days. Following early non-detections, X-ray and radio emission were discovered at the transient’s position ~9 and ~16 days, respectively, after the merger. Both the X-ray and radio emission likely arise from a physical process that is distinct from the one that generates the UV/optical/near-infrared emission. No ultra-high-energy gamma-rays and no neutrino candidates consistent with the source were found in follow-up searches. These observations support the hypothesis that GW170817 was produced by the merger of two neutron stars in NGC4993 followed by a short gamma-ray burst (GRB 170817A) and a kilonova/macronova powered by the radioactive decay of r-process nuclei synthesized in the ejecta